<DOC>
	<DOCNO>NCT02595268</DOCNO>
	<brief_summary>The purpose study evaluate effect steady-state concentration JNJ-63623872 single-dose pharmacokinetics pitavastatin healthy participant .</brief_summary>
	<brief_title>A Study Investigate Effect JNJ-63623872 Pitavastatin Healthy Participants</brief_title>
	<detailed_description>This Phase 1 , open-label ( identity study drug know participant study staff ) , sequential study healthy volunteer investigate potential Pharmacokinetics ( PK ) effect JNJ-872 pitavastatin . The study consist Screening Phase ( 28 day ) , Treatment Phase ( Day 1 - Day 12 ) , Follow ( 10-14 day 30-35 day last study drug intake drop ) . The total duration study approximately 2 month . Participants sequentially receive follow treatment : single oral dose pitavastatin 1 milligram ( mg ) Day 1 ; JNJ-63623872 600 mg twice daily Days 4 12 , single oral dose pitavastatin 1 mg administer morning Day 9 . All study drug intake take orally , fed condition ( within approximately 10 minute completion meal ) . Blood sample collect assess pharmacokinetic parameter . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Participant must willing able adhere prohibition restriction specify protocol A female participant childbearing potential must negative serum betahuman chorionic gonadotropin test Screening negative urine pregnancy test Day 1 A female participant must agree donate egg ( ovum , oocytes ) throughout study least 90 day receive last dose study drug A male participant sexually active woman childbearing potential must agree use two effective method birth control , male participant must also agree donate sperm throughout study 90 day receive last dose study drug Participant must body mass index ( BMI ; weight kg divide square height meter ) 18.0 30.0 kilogram per square meter ( kg/m^2 ) , extremes include Participant history illness , opinion Investigator , might confound result study pose additional risk administer study drug participant could prevent , limit confound protocol specify assessment . This may include limited renal dysfunction [ calculate creatinine clearance 60 milliliter per minute ( mL/min ) Screening ] , significant cardiac , vascular , pulmonary , gastrointestinal ( significant diarrhea , gastric stasis , constipation Investigator 's opinion could influence drug absorption bioavailability ) , endocrine , neurologic , hematologic , rheumatologic , psychiatric , neoplastic , metabolic disturbance , predisposition myopathy Participants one laboratory abnormality specify protocol , Screening define World Health Organization ( WHO ) Toxicity Grading Scale Participant past history clinically significant heart arrhythmia ( extrasystoli , tachycardia rest ) risk factor Torsade de Pointes syndrome ( example , hypokalemia , family history long QT Syndrome ) Participants history clinically significant skin disease , limited , dermatitis , eczema , drug rash , psoriasis , food allergy , urticaria Participants history clinically significant drug allergy , limited , sulfonamides penicillin , drug allergy witness previous study experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Pitavastatin</keyword>
	<keyword>JNJ-63623872</keyword>
</DOC>